These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14506749)

  • 1. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.
    Neudert M; Fischer C; Krempien B; Bauss F; Seibel MJ
    Int J Cancer; 2003 Nov; 107(3):468-77. PubMed ID: 14506749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
    Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
    Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein.
    Bäuerle T; Adwan H; Kiessling F; Hilbig H; Armbruster FP; Berger MR
    Int J Cancer; 2005 Jun; 115(2):177-86. PubMed ID: 15688393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
    Kurth AA; Kim SZ; Sedlmeyer I; Bauss F; Shea M
    Bone; 2002 Jan; 30(1):300-6. PubMed ID: 11792601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
    J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein.
    Bäuerle T; Peterschmitt J; Hilbig H; Kiessling F; Armbruster FP; Berger MR
    Int J Oncol; 2006 Mar; 28(3):573-83. PubMed ID: 16465361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
    Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
    J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
    Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
    Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
    van Beek ER; Lowik CW; van Wijngaarden J; Ebetino FH; Papapoulos SE
    Breast Cancer Res Treat; 2009 Nov; 118(2):307-13. PubMed ID: 18989771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
    Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.
    Yi B; Williams PJ; Niewolna M; Wang Y; Yoneda T
    Cancer Res; 2002 Feb; 62(3):917-23. PubMed ID: 11830552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
    Abdelaziz DM; Stone LS; Komarova SV
    Breast Cancer Res Treat; 2014 Jan; 143(2):227-37. PubMed ID: 24327332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.
    Sohara Y; Shimada H; Scadeng M; Pollack H; Yamada S; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2003 Jun; 63(12):3026-31. PubMed ID: 12810621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies.
    Amhlaoibh RN; Hoegh-Andersen P; Brünner N; Sørensen A; Winding B; Holst-Hansen C; Karsdal MA; Engsig MT; Delaissé JM; Heegaard AM
    Clin Exp Metastasis; 2004; 21(1):65-74. PubMed ID: 15065604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.